B. Riley Securities has elevated The Oncology Institute as its Best Idea from the firm’s May conference, reiterating a Buy recommendation and assigning an $8 price target. The research house emphasized that a recent refinancing cleared a short-term financing overhang tied to convertible debt, reshaping the company’s near-term capital structure.
The refinancing addressed an $86 million convertible note that had been scheduled to mature in August 2027. The Oncology Institute satisfied the obligation using a $75 million term loan provided by OrbiMed together with $11 million drawn from the company’s cash balance, completing the transaction without issuing additional equity. The replacement debt carries a maturity in 2031 and is expected to carry an interest rate in the range of 9% to 12%.
B. Riley analysts Yuan Zhi and Liwen Wang attributed the company’s ability to secure the new term loan in part to recently improved free cash flow, citing a $20 million improvement at the midpoint of 2026 guidance. The analysts also noted expectations for continued quarterly expansion in the company’s capitated contract revenue and dispensary operations as the company moves toward its second quarter 2026 earnings call in early August.
For the second quarter of 2026 specifically, B. Riley models revenue of $152.8 million, which sits below the consensus estimate of $155.2 million; the firm’s forecast reflects an assumption of stronger revenue growth later in the year. Management has provided adjusted EBITDA guidance for the quarter of negative $1 million to positive $1 million, a range management says reflects seasonal factors such as deductible resets and continued ramp-up of operations in Florida.
Company management reiterated a multi-year growth target that includes an annual revenue growth rate of roughly 20%, with a goal of reaching $1 billion in revenue by 2028 accompanied by $50 million to $60 million in adjusted EBITDA. B. Riley said that resolving the near-term financing constraint without an equity raise should help the market re-engage with the company’s high-growth healthcare services profile.
Outside of B. Riley’s assessment, several other firms updated their views on The Oncology Institute. Lake Street initiated coverage with a Buy rating and a $10 price target. BTIG raised its price target to $9, and Needham increased its target to $7.
Context and implications
The refinancing replaces convertible debt due in 2027 with a longer-dated term loan maturing in 2031, converting a short-term maturity risk into a multi-year repayment schedule. B. Riley’s projection for second quarter 2026 revenue is modestly below consensus, while management guidance points to a seasonal improvement in adjusted EBITDA and a path to substantial revenue and adjusted EBITDA growth by 2028.
What to watch next
- Second quarter 2026 earnings call in early August, where management is expected to provide additional detail on quarterly progress and operational ramps.
- Quarterly trends in capitated contracts and dispensary operations, which B. Riley expects to contribute to continued top-line growth.
- Interest expense and cash flow impacts from the new term loan, given the anticipated interest range of 9% to 12%.